

Ludovic Lhermitte

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8377108/publications.pdf>

Version: 2024-02-01

45
papers

2,035
citations

361413

20
h-index

289244

40
g-index

46
all docs

46
docs citations

46
times ranked

3568
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinico-biological features of T-cell acute lymphoblastic leukemia with fusion proteins. <i>Blood Cancer Journal</i> , 2022, 12, 14.	6.2	10
2	Effective Anti-“SARS-CoV-2 Immune Response in Patients With Clonal Mast Cell Disorders. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, 10, 1356-1364.e2.	3.8	2
3	Oncogenetic landscape of T-cell lymphoblastic lymphomas compared to T-cell acute lymphoblastic leukemia. <i>Modern Pathology</i> , 2022, 35, 1227-1235.	5.5	5
4	Targeted deep sequencing reveals clonal and subclonal mutational signatures in Adult T-cell leukemia/lymphoma and defines an unfavorable indolent subtype. <i>Leukemia</i> , 2021, 35, 764-776.	7.2	24
5	Chemotherapy or allogeneic transplantation in high-risk Philadelphia chromosome-“negative adult lymphoblastic leukemia. <i>Blood</i> , 2021, 137, 1879-1894.	1.4	48
6	<i>IKZF1</i> alterations predict poor prognosis in adult and pediatric T-ALL. <i>Blood</i> , 2021, 137, 1690-1694.	1.4	8
7	A transcriptomic continuum of differentiation arrest identifies myeloid interface acute leukemias with poor prognosis. <i>Leukemia</i> , 2021, 35, 724-736.	7.2	8
8	Automated identification of leukocyte subsets improves standardization of database-guided expert-supervised diagnostic orientation in acute leukemia: a EuroFlow study. <i>Modern Pathology</i> , 2021, 34, 59-69.	5.5	15
9	Long-term outcome of imatinib 400%mg compared to imatinib 600%mg or imatinib 400%mg daily in combination with cytarabine or pegylated interferon alpha 2a for chronic myeloid leukaemia: results from the French SPIRIT phase III randomised trial. <i>Leukemia</i> , 2021, 35, 2332-2345.	7.2	15
10	Adenylate kinase 2 expression and addiction in T-ALL. <i>Blood Advances</i> , 2021, 5, 700-710.	5.2	7
11	Oncogenetic landscape and clinical impact of IDH1 and IDH2 mutations in T-ALL. <i>Journal of Hematology and Oncology</i> , 2021, 14, 74.	17.0	10
12	The association of Greig syndrome and mastocytosis reveals the involvement of the hedgehog pathway in advanced mastocytosis. <i>Blood</i> , 2021, 138, 2396-2407.	1.4	5
13	Epidemiology, clinical picture and long-term outcomes of <i>FIP1L1-PDGFRα</i> -positive myeloid neoplasm with eosinophilia: Data from 151 patients. <i>American Journal of Hematology</i> , 2020, 95, 1314-1323.	4.1	37
14	Low level CpG island promoter methylation predicts a poor outcome in adult T-cell acute lymphoblastic leukemia. <i>Haematologica</i> , 2020, 105, 1575-1581.	3.5	10
15	<i>CBFβ-SMMHC</i> Affects Genome-wide Polycomb Repressive Complex 1 Activity in Acute Myeloid Leukemia. <i>Cell Reports</i> , 2020, 30, 299-307.e3.	6.4	6
16	Adult T-cell acute lymphoblastic leukemias with IL7R pathway mutations are slow-responders who do not benefit from allogeneic stem-cell transplantation. <i>Leukemia</i> , 2020, 34, 1730-1740.	7.2	21
17	Real Time Pathological and Molecular Characterization of Aggressive B-Cell Lymphomas Based on a National Network. a Lysa Project. <i>Blood</i> , 2020, 136, 22-23.	1.4	2
18	Standardization of Flow Cytometric Immunophenotyping for Hematological Malignancies: The FranceFlow Group Experience. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2019, 95, 1008-1018.	1.5	18

#	ARTICLE	IF	CITATIONS
19	Omaliuzumab Therapy for Mast Cell-Mediator Symptoms in Patients with ISM, CM, MMAS, and MCAS. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 2387-2395.e3.	3.8	42
20	<i>DNMT3A</i> mutation is associated with increased age and adverse outcome in adult T-cell acute lymphoblastic leukemia. <i>Haematologica</i> , 2019, 104, 1617-1625.	3.5	40
21	Clinical and biological features of PTPN2-deleted adult and pediatric T-cell acute lymphoblastic leukemia. <i>Blood Advances</i> , 2019, 3, 1981-1988.	5.2	12
22	The Combination of Venetoclax and Tofacitinib Induced Hematological Responses in Patients with Relapse/ Refractory T-ALL with BCL2 Expression and Surface IL7R Expression or IL7R-Pathway Mutations (On behalf of the GRAALL). <i>Blood</i> , 2019, 134, 1339-1339.	1.4	2
23	BCL-2 Is Expressed in Advanced Mastocytosis and Midaustorin Induces Venetoclax Sensitivity of Mast Leukemia Cell Lines. <i>Blood</i> , 2019, 134, 1683-1683.	1.4	3
24	A "foamy" mastocytosis case. <i>Blood</i> , 2018, 131, 586-586.	1.4	0
25	Dominant-negative IKZF1 mutations cause a T, B, and myeloid cell combined immunodeficiency. <i>Journal of Clinical Investigation</i> , 2018, 128, 3071-3087.	8.2	133
26	Omaliuzumab: Efficacy and Safety in Mast Cell Disorders. <i>Blood</i> , 2018, 132, 4280-4280.	1.4	0
27	Longitudinal Evolution and Clinical Impact of Subclonal Mutational Architecture in Adult T Cell Leukemia/Lymphoma. <i>Blood</i> , 2018, 132, 2841-2841.	1.4	0
28	Masitinib for treatment of severely symptomatic indolent systemic mastocytosis: a randomised, placebo-controlled, phase 3 study. <i>Lancet, The</i> , 2017, 389, 612-620.	13.7	95
29	Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia. <i>Blood</i> , 2017, 129, 347-357.	1.4	323
30	Response to 5-azacytidine in a patient with <i>TET2</i> -mutated angioimmunoblastic T-cell lymphoma and chronic myelomonocytic leukaemia preceded by an EBV-positive large B-cell lymphoma. <i>Hematological Oncology</i> , 2017, 35, 864-868.	1.7	33
31	Early Response-Based Therapy Stratification Improves Survival in Adult Early Thymic Precursor Acute Lymphoblastic Leukemia: A Group for Research on Adult Acute Lymphoblastic Leukemia Study. <i>Journal of Clinical Oncology</i> , 2017, 35, 2683-2691.	1.6	134
32	An early thymic precursor phenotype predicts outcome exclusively in HOXA-overexpressing adult T-cell acute lymphoblastic leukemia: a Group for Research in Adult Acute Lymphoblastic Leukemia study. <i>Haematologica</i> , 2016, 101, 732-740.	3.5	53
33	Genetically distinct leukemic stem cells in human CD34 ^{hi} acute myeloid leukemia are arrested at a hemopoietic precursor-like stage. <i>Journal of Experimental Medicine</i> , 2016, 213, 1513-1535.	8.5	120
34	Minimal residual disease monitoring by 8-color flow cytometry in mantle cell lymphoma: an EU-MCL and LYSA study. <i>Haematologica</i> , 2016, 101, 336-345.	3.5	50
35	Interleukin-15-Dependent T-Cell-like Innate Intraepithelial Lymphocytes Develop in the Intestine and Transform into Lymphomas in Celiac Disease. <i>Immunity</i> , 2016, 45, 610-625.	14.3	131
36	Triggering the TCR Developmental Checkpoint Activates a Therapeutically Targetable Tumor Suppressive Pathway in T-cell Leukemia. <i>Cancer Discovery</i> , 2016, 6, 972-985.	9.4	33

#	ARTICLE	IF	CITATIONS
37	Mastocytoses systémiques : aspects cytologiques et histologiques en hématologie. Revue Francophone Des Laboratoires, 2016, 2016, 31-41.	0.0	0
38	Targeting IRAK1 in T-Cell acute lymphoblastic leukemia. Oncotarget, 2015, 6, 18956-18965.	1.8	16
39	ASXL1 but Not TET2 Mutations Adversely Impact Overall Survival of Patients Suffering Systemic Mastocytosis with Associated Clonal Hematologic Non-Mast-Cell Diseases. PLoS ONE, 2014, 9, e85362.	2.5	65
40	RUNX1-dependent RAG1 deposition instigates human TCR- β locus rearrangement. Journal of Experimental Medicine, 2014, 211, 1821-1832.	8.5	19
41	Toward a <i>NOTCH1/FBXW7/RAS/PTEN</i> -Based Oncogenetic Risk Classification of Adult T-Cell Acute Lymphoblastic Leukemia: A Group for Research in Adult Acute Lymphoblastic Leukemia Study. Journal of Clinical Oncology, 2013, 31, 4333-4342.	1.6	202
42	Mast cell leukemia. Blood, 2013, 121, 1285-1295.	1.4	153
43	Mast Cell Sarcoma: A Rare and Aggressive Entity—Report of Two Cases and Review of the Literature. Journal of Clinical Oncology, 2013, 31, e90-e97.	1.6	43
44	TLX Homeodomain Oncogenes Mediate T Cell Maturation Arrest in T-ALL via Interaction with ETS1 and Suppression of TCR β Gene Expression. Cancer Cell, 2012, 21, 563-576.	16.8	81
45	Eight Colors Flow Cytometry Phenotyping for Blood Minimal Residual Disease Monitoring in Hairy Cell Leukaemia Patients.. Blood, 2009, 114, 1609-1609.	1.4	1